| Identification | Back Directory | [Name]
NDB | [CAS]
1660153-08-1 | [Synonyms]
NDB
NDB >=98% (HPLC)
Benzamide, 2,6-dichloro-4-(dimethylamino)-N-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(phenylmethyl)- | [Molecular Formula]
C26H28Cl2N2O2 | [MOL File]
1660153-08-1.mol | [Molecular Weight]
471.42 |
| Chemical Properties | Back Directory | [Boiling point ]
628.6±55.0 °C(Predicted) | [density ]
1.258±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 10mg/mL, clear | [form ]
Solid | [pka]
11.35±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research[1]. | [Biological Activity]
NDB is a selective antagonist of human Farnesoid X receptor α (FXRα) th at effectively modulates FXRα down-stream genes. | [in vivo]
NDB (24 mg/kg; intraperitoneal injection; once a day; for 4 weeks) efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and BSEP in db/db mice[1]. | Animal Model: | Male C57BL/6J db/db mice (8 weeks of age)[1] | | Dosage: | 24 mg/kg | | Administration: | Intraperitoneal injection; once a day; for 4 weeks | | Result: | Decreased the gene expressions of PEPCK, G6-pase, small heterodimer partner, and BSEP.
|
| [References]
[1] Xing Xu, et al. Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor. J Biol Chem. 2015 Aug 7;290(32):19888-99. DOI:10.1074/jbc.M114.630475 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|